ReviewBMC cancer2026
Persistent follicular cystitis following intravesical gemcitabine: a case series and literature review.
Review in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntravesical gemcitabine is widely used for non-muscle-invasive bladder cancer (NMIBC) due to its favorable safety profile. While transient irritative symptoms are common, persistent inflammatory cystitis remains poorly characterized.
methodsWe conducted a retrospective observational study at a tertiary referral center. Patients receiving intravesical gemcitabine following transurethral resection of bladder tumor (TURBT) between 2022 and 2024 were screened using a stringent operational definition: (1) irritative symptoms lasting ≥ 8 weeks; (2) persistent sterile pyuria with negative urine cultures; (3) cystoscopic inflammatory changes (follicular elevations with diffuse hyperemia); (4) absence of tumor recurrence; (5) failure of conservative therapy; and (6) histopathological confirmation. Clinical characteristics and outcomes following conversion to mitomycin C (MMC) were analyzed.
resultsAmong 101 patients treated with intravesical gemcitabine, two (1.98%) met the predefined criteria. Patient A (70-year-old female) developed persistent urinary frequency, urgency, and dysuria lasting 4 months. Patient B (30-year-old male) experienced similar symptoms lasting 3 months. Both presented with sterile pyuria, microscopic hematuria, and cystoscopic findings of follicular elevations with diffuse hyperemia. Biopsy confirmed chronic inflammatory infiltration with lymphoid follicle formation. Following discontinuation of gemcitabine and conversion to MMC, both patients experienced complete symptomatic resolution within 6-8 weeks, with marked attenuation of inflammatory cystoscopic findings.
conclusionsPersistent follicular cystitis following intravesical gemcitabine is a rare but clinically significant entity. Early recognition and therapeutic conversion to MMC can prevent prolonged morbidity. Larger studies are warranted to determine incidence and risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.